Endo Pharmaceutical Holdings Inc. (ENDP): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Endo Pharmaceutical Holdings ( ENDP) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Endo Pharmaceutical Holdings fell 92 cents (-2.8%) to $31.51 on heavy volume. Throughout the day, 4.2 million shares of Endo Pharmaceutical Holdings exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in price between $31.14-$33.03 after having opened the day at $31.74 as compared to the previous trading day's close of $32.43. Other companies within the Drugs industry that declined today were: Sarepta Therapeutics ( SRPT), down 15.6%, MEI Pharma ( MEIP), down 14.8%, Cell Therapeutics ( CTIC), down 13.6%, and Biosante Pharmaceuticals ( BPAX), down 11.1%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Pharmaceutical Holdings has a market cap of $3.75 billion and is part of the health care sector. Shares are down 7.1% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Endo Pharmaceutical Holdings a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Endo Pharmaceutical Holdings as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the positive front, Arqule ( ARQL), up 22.1%, Insmed ( INSM), up 18%, Synthetic Biologics ( SYN), up 13%, and Neuralstem ( CUR), up 12.3%, were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds